Oncolytic adenovirus Delta-24- RGD engineered to express 4-1BBL or OX40L as therapeutic approach for diffuse intrinsic pontine gliomas
Pediatric tumors appear during childhood and adolescence and are diagnosed from 0 to 19 years old.1 The WHO estimates that 400,000 cases are diagnosed every year globally, which account for about 1% of all cancer diagnoses. 2 Pediatric tumors differ substantially from tumors occurring in adults....
| Main Authors: | , , |
|---|---|
| Format: | info:eu-repo/semantics/doctoralThesis |
| Language: | eng |
| Published: |
Universidad de Navarra
2023
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10171/65228 |
| _version_ | 1795386254593884160 |
|---|---|
| author | Laspidea, V. (Virginia) Alonso-Roldán, M.M. (Marta María) Patiño-García, A. (Ana) |
| author_facet | Laspidea, V. (Virginia) Alonso-Roldán, M.M. (Marta María) Patiño-García, A. (Ana) |
| author_sort | Laspidea, V. (Virginia) |
| collection | DSpace |
| description | Pediatric tumors appear during childhood and adolescence and are diagnosed from 0 to
19 years old.1 The WHO estimates that 400,000 cases are diagnosed every year
globally, which account for about 1% of all cancer diagnoses.
2 Pediatric tumors differ
substantially from tumors occurring in adults. While adult cancer occurs due to the
accumulation of genetic mutations and cell damage with age, pediatric tumors are
usually caused by a blockage in the maturation of immature developing cell types.
Therefore, the latter show much lower genetic aberrations.
3,4 The most frequently
diagnosed tumors during childhood are hematological malignancies (including leukemia
and lymphoma), followed by tumors of the central nervous system (CNS). Specifically,
leukemia (24.7%), tumors of the central nervous system (17.2%), non-Hodgking
lymphoma (7.5%), Hodgking lymphoma (6.5%), soft-tissue sarcoma (5.9%) and bone
tumors (4-8%) are the most common groups5 (Figure 1). In this work, we will focus on
brain tumors, and specifically on diffuse midline gliomas (DMGs). |
| format | info:eu-repo/semantics/doctoralThesis |
| id | oai:dadun.unav.edu:10171-65228 |
| institution | Universidad de Navarra |
| language | eng |
| publishDate | 2023 |
| publisher | Universidad de Navarra |
| record_format | dspace |
| spelling | oai:dadun.unav.edu:10171-652282023-02-06T06:05:16Z Oncolytic adenovirus Delta-24- RGD engineered to express 4-1BBL or OX40L as therapeutic approach for diffuse intrinsic pontine gliomas Laspidea, V. (Virginia) Alonso-Roldán, M.M. (Marta María) Patiño-García, A. (Ana) Materias Investigacion::Ciencias de la Salud::Oncología Pediatric brain tumors Oncolytic virotherapy T regulatory cells Treg Delta-24-ACT Delta-24-RGDOX Intrinsic pontine gliomas Pediatric tumors appear during childhood and adolescence and are diagnosed from 0 to 19 years old.1 The WHO estimates that 400,000 cases are diagnosed every year globally, which account for about 1% of all cancer diagnoses. 2 Pediatric tumors differ substantially from tumors occurring in adults. While adult cancer occurs due to the accumulation of genetic mutations and cell damage with age, pediatric tumors are usually caused by a blockage in the maturation of immature developing cell types. Therefore, the latter show much lower genetic aberrations. 3,4 The most frequently diagnosed tumors during childhood are hematological malignancies (including leukemia and lymphoma), followed by tumors of the central nervous system (CNS). Specifically, leukemia (24.7%), tumors of the central nervous system (17.2%), non-Hodgking lymphoma (7.5%), Hodgking lymphoma (6.5%), soft-tissue sarcoma (5.9%) and bone tumors (4-8%) are the most common groups5 (Figure 1). In this work, we will focus on brain tumors, and specifically on diffuse midline gliomas (DMGs). 2023-01-31T13:41:54Z 2023-01-31T13:41:54Z 2023-01-31 2022-12-13 info:eu-repo/semantics/doctoralThesis https://hdl.handle.net/10171/65228 eng info:eu-repo/semantics/openAccess application/pdf Universidad de Navarra |
| spellingShingle | Materias Investigacion::Ciencias de la Salud::Oncología Pediatric brain tumors Oncolytic virotherapy T regulatory cells Treg Delta-24-ACT Delta-24-RGDOX Intrinsic pontine gliomas Laspidea, V. (Virginia) Alonso-Roldán, M.M. (Marta María) Patiño-García, A. (Ana) Oncolytic adenovirus Delta-24- RGD engineered to express 4-1BBL or OX40L as therapeutic approach for diffuse intrinsic pontine gliomas |
| title | Oncolytic adenovirus Delta-24- RGD engineered to express 4-1BBL or OX40L as therapeutic approach for diffuse intrinsic pontine gliomas |
| title_full | Oncolytic adenovirus Delta-24- RGD engineered to express 4-1BBL or OX40L as therapeutic approach for diffuse intrinsic pontine gliomas |
| title_fullStr | Oncolytic adenovirus Delta-24- RGD engineered to express 4-1BBL or OX40L as therapeutic approach for diffuse intrinsic pontine gliomas |
| title_full_unstemmed | Oncolytic adenovirus Delta-24- RGD engineered to express 4-1BBL or OX40L as therapeutic approach for diffuse intrinsic pontine gliomas |
| title_short | Oncolytic adenovirus Delta-24- RGD engineered to express 4-1BBL or OX40L as therapeutic approach for diffuse intrinsic pontine gliomas |
| title_sort | oncolytic adenovirus delta-24- rgd engineered to express 4-1bbl or ox40l as therapeutic approach for diffuse intrinsic pontine gliomas |
| topic | Materias Investigacion::Ciencias de la Salud::Oncología Pediatric brain tumors Oncolytic virotherapy T regulatory cells Treg Delta-24-ACT Delta-24-RGDOX Intrinsic pontine gliomas |
| url | https://hdl.handle.net/10171/65228 |
| work_keys_str_mv | AT laspideavvirginia oncolyticadenovirusdelta24rgdengineeredtoexpress41bblorox40lastherapeuticapproachfordiffuseintrinsicpontinegliomas AT alonsoroldanmmmartamaria oncolyticadenovirusdelta24rgdengineeredtoexpress41bblorox40lastherapeuticapproachfordiffuseintrinsicpontinegliomas AT patinogarciaaana oncolyticadenovirusdelta24rgdengineeredtoexpress41bblorox40lastherapeuticapproachfordiffuseintrinsicpontinegliomas |